S-benzyl-L-cysteine ethyl ester | 953-18-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: S-benzyl-L-cysteine ethyl ester
• 英文别名: ethyl S-benzyl-L-cysteinate；S-benzyl-L-cysteine ethyl ester；S-Benzyl-L-cystein-aethylester；ethyl (2R)-2-amino-3-benzylsulfanylpropanoate
• CAS: 953-18-4
• 化学式: C₁₂H₁₇NO₂S
• 分子量: 239.338
• InChiKey: CNQSZDMYASSXPV-NSHDSACASA-N

物化性质

• 沸点：
  191-195 °C(Press: 0.2 Torr)
• 密度：
  1.140±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  77.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  S-benzyl-L-cysteine ethyl ester 在 sodium hydroxide 、 二丁基二氯化锡 、 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 48.0h， 生成 3(S)-<<(1R)-2-(benzylthio)-1-carboxyethyl>amino>-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-ethanoic acid
  参考文献：
  名称：

  Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives

  摘要：

  The preparation of a series of 3-amino-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine-1-acetic acid derivatives 5a-y by reductive amination of 2,3,4,5-tetrahydro-1H-1-benzazepine-2,3-dione (7) with L-amino acid derivatives is described. The compounds were tested for inhibition of angiotensin converting enzyme. The structure-activity profile of the series is discussed. Compound 5a was especially potent when tested in dogs for inhibition of angiotensin I pressor response, having an ID50 = 0.07 mg/kg po.

  DOI：

  10.1021/jm00149a010
• 作为产物：
  描述：

  S-苄基-L-半胱氨酸乙酯盐酸盐 在 三乙胺 作用下， 以 乙酸乙酯 为溶剂， 反应 0.5h， 生成 S-benzyl-L-cysteine ethyl ester
  参考文献：
  名称：

  Dymicky, Michael; Byler, D. Michael, Organic Preparations and Procedures International, 1991, vol. 23, # 1, p. 93 - 102

  摘要：

  DOI：

文献信息

• Synthesis of [2-Serine, 8-VaIine]-Human Calcitonin
  作者：Sukekatsu Nozaki

  DOI：10.1246/bcsj.51.2995

  日期：1978.10

  The [2-serine, 8-valine]-analog of human calcitonin (1) was synthesized by the liquid phase method. Analog 1 was built up from five fragments with minimized protection for the side functional groups. These fragments were linked step wise to the C-terminal fragments by the azide method. A gel filtration was effectively applied for the purification of the resulting pep tide in each fragment condensation. Analog 1 had about the same hypocalcemic activity as that of human calcitonin. The result showed that the high activity of eel or salmon calcitonin 1 or 2 is not ascribable only to the amino acid sequence of their N-terminal decapeptide.

  [2-丝氨酸, 8-缬氨酸]型人降钙素(1)通过液相法合成。模拟物1由五个片段构建而成，这些片段侧功能团保护最少。这些片段通过叠氮法逐步与C末端片段连接。每一步片段缩合后，凝胶过滤法有效地应用于所得肽的纯化。模拟物1具有与人降钙素相似的降血钙活性。结果表明，鳗鱼或鲑鱼降钙素1或2的高活性并不仅仅归因于其N端十肽的氨基酸序列。
• Dehydrooligopeptides. I. The Facile Coupling of α-Amino Acids with α-Dehydroamino Acids to Dehydrodipeptides
  作者：Yasuchika Yonezawa、Chung-gi Shin、Yuji Ono、Juji Yoshimura

  DOI：10.1246/bcsj.53.2905

  日期：1980.10

  N-Cbz- or N-Tos-α-dehydroamino acid (DHA) and its ester were prepared by the condensation of 2-oxo carboxylic acid or ester with benzyl carbamate or p-toluenesulfonamide. Subsequently, the N-protected DHA and its N-free ester thus obtained were coupled with several L-α-amino acid esters and N-protected (Boc or Cbz)-L-α-amino acid respectively by the usual peptide synthetic methods to give a number

  N-Cbz-或N-Tos-α-脱氢氨基酸（DHA）及其酯是通过2-氧代羧酸或酯与氨基甲酸苄酯或对甲苯磺酰胺缩合制备的。随后，将由此获得的 N-保护的 DHA 及其无 N-酯分别与几种 L-α-氨基酸酯和 N-保护的（Boc 或 Cbz）-L-α-氨基酸通过通常的肽合成方法偶联到给出许多不同类型的脱氢二肽。获得的所有新 DHA 和脱氢二肽的构型均显示为 (Z)-几何。
• SUPPORTED METAL CATALYSTS
  申请人：Bishop Peter Trenton

  公开号：US20130072722A1

  公开（公告）日：2013-03-21

  The present invention relates to supported metal catalysts, wherein the catalysts are modified by at least one amine, a method for the preparation thereof and hydrogenation processes utilising the supported metal catalysts.

  本发明涉及支持金属催化剂，其中催化剂经过至少一种胺的改性，及其制备方法和利用支持金属催化剂的氢化过程。
• Dipeptide derivatives
  申请人：——

  公开号：US20020183260A1

  公开（公告）日：2002-12-05

  Compounds of the formula 1 wherein R, R 1 , COOR 2 , R 3 -R 7 , alk, and X have meaning as defined, such being useful as dual inhibitors of angiotensin converting enzyme and neutral endopeptidase, as well as inhibitors of endothelin converting enzyme.

  式1中的化合物，其中R、R1、COOR2、R3-R7、alk和X的含义如所定义，这些化合物可作为抑制肾素-血管紧张素转化酶和中性内肽酶的双重抑制剂，同时也可作为内皮素转化酶的抑制剂。
• Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
  申请人：SCHERING CORPORATION

  公开号：EP0050800A1

  公开（公告）日：1982-05-05

  Disclosed are novel carboxyalkyl dipeptides which are useful as inhibitors of angiotensinconverting enzyme and as antihypertensive agents, having the formula and the pharmaceutically acceptable salts thereof, wherein R and R6 are for example hydroxy, lower alkoxy or arylloweralkoxy; R' is for example hydrogen, alkyl, lower alkoxy or aryloxy; R2 and R are the same or different and are hydrogen or lower alkyl; R3 is for example lower alkyl or phenyl lower alkyl; R4 and R5 are selected from hydrogen, lower alkyl and Z, or R4 and R5 taken together form a group represented by Q, U, V, Y, D or E wherein wherein X' and X2 independent of each other are 0, S or CH2, R8 and R9 independent of each other are lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl having 3 to 8 carbon atoms, hydroxy lower alkyl or -(CH2)nAr, wherein n is 0, 1, 2 or 3 or R8 and R9 taken together form a bridge W, wherein W is a single bond or a methylene bridge or a substituted methylene bridge when at least one of X' and X2 is methylene, or W is an alkylene or substituted alkylene bridge having 2 or 3 carbon atoms; with the proviso that at least one of R4 and R5 is Z; wherein L is O or S. The compounds can be prepared according to known methods such as for example by condensation of an aminoacid XXI with an aminoacid XVII wherein X1, X2 and W are as defined above; wherein G is oxygen, sulfur or CH2;

  本发明公开了可用作血管紧张素转换酶抑制剂和降压药的新型羧烷基二肽，其化学式为 其中 R 和 R6 例如是羟基、低级烷氧基或芳基低级烷氧基；R'例如是氢、烷基、低级烷氧基或芳基氧基；R2 和 R 相同或不同，并且是氢或低级烷基；R3 例如是低级烷基或苯基低级烷基；R4 和 R5 选自氢、低级烷基和 Z，或 R4 和 R5 共同形成由 Q、U、V、Y、D 或 E 代表的基团，其中 其中 X' 和 X2 互不相关，分别为 0、S 或 CH2，R8 和 R9 互不相关，分别为低级烷基、低级烯基、低级炔基、具有 3 至 8 个碳原子的环烷基、羟基低级烷基或-(CH2)nAr，其中 n 为 0、1、其中 W 是单键或亚甲基桥或取代的亚甲基桥（当 X' 和 X2 中至少有一个是亚甲基时），或 W 是具有 2 或 3 个碳原子的亚烷基或取代的亚烷基桥；但 R4 和 R5 中至少有一个是 Z； 这些化合物可根据已知方法制备，例如通过氨基酸 XXI 与氨基酸 XVII 缩合 其中 X1、X2 和 W 如上定义； 其中 G 为氧、硫或 CH2；